Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...

As Ozempic enters India, here is how semaglutide and GLP-1 drugs work, why demand is rising, and how they fit into India's ...

With India facing over 101 million cases of diabetes and rising obesity levels, the drug could play a significant role in ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic (semaglutide) for use in October this year for adults with type 2 diabetes. The company will sell the ...

Novo Nordisk launches Ozempic in India, outlining prices, doses, and its bid to capture rising diabetes and weight-loss ...

Novo Nordisk has launched Ozempic, its once-weekly semaglutide injection, in India with prices starting at Rs 8,800. Approved ...

Weight-loss jabs, such as Ozempic and Wegovy, have revolutionised the way we treat obesity in humans, and scientists now want ...

Semaglutide and tirzepatide, the latter marketed by US-based Eli Lilly in India as Mounjaro, belong to the GLP-1 class of ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming ...

Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday, pricing the lowest dose of 0 ...

Ozempic, a once-weekly injectable approved by the U.S. Food and Drug Administration in 2017 for type 2 diabetes, has become a ...